Teva Pharmaceutical Industries (TEVJF) Total Liabilities (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Total Liabilities across 18 years of filings, most recently posting $31.8 billion for Q1 2026.

• Quarterly Total Liabilities fell 1.05% year-over-year to $31.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.8 billion (down 1.05% YoY) and the FY2025 annual result came in at $32.8 billion, down 2.3% from the prior year.
• Total Liabilities eased to $31.8 billion in Q1 2026, from $32.8 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $36.8 billion in Q1 2022 and troughed at $31.8 billion in Q1 2026.
• A 5-year average of $34.4 billion and a median of $34.8 billion in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities gained 1.92% — and 2025, when it fell 8.75%.
• Tracing TEVJF's Total Liabilities over 5 years: stood at $35.4 billion in 2022, then decreased by 0.17% to $35.4 billion in 2023, then retreated by 4.94% to $33.6 billion in 2024, then dropped by 2.3% to $32.8 billion in 2025, then slipped by 3.12% to $31.8 billion in 2026.
• Business Quant data shows TEVJF's Total Liabilities at $31.8 billion in Q1 2026, $32.8 billion in Q4 2025, and $32.6 billion in Q3 2025.